An Open-label Study of Efficacy, Safety and Tolerability of Liposomal Amikacin for Inhalation (LAI) Once Daily in Addition to Standard Multi-antibiotic Therapy in the Treatment of Mycobacterium Abscessus Lung Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Amikacin (Primary)
- Indications Mycobacterial infections
- Focus Therapeutic Use
- 30 Jan 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 30 Jan 2019 Planned primary completion date changed from 1 Mar 2019 to 1 May 2019.
- 25 Jun 2018 Planned End Date changed from 1 Dec 2019 to 1 Jun 2019.